Osborne Clarke

Firm overview:

Osborne Clarke combines specialist IP litigation and prosecution strengths within a full-service international law firm. Founded in 1748 and headquartered in London, the firm now spans 26 offices worldwide. Its patent practice has rapidly developed in the UK, underpinned by a reputation for tackling complex disputes in life sciences and telecommunications, particularly in SEP/FRAND cases.

The team supports R&D-focused clients—including those operating in biotech, medtech, software, telecoms, and clean tech—providing integrated services from prosecution and oppositions to high-stakes multi-jurisdictional litigation and licensing strategy. High-profile achievements include acting as co-counsel for Unwired Planet in its landmark Supreme Court case with Huawei.

Team overview:

Osborne Clarke’s IP practice is led in London by Arty Rajendra, who is noted for handling SEP/FRAND and competition disputes and described as “very good” by an industry peer.

Key partners include Tim Harris, Will James, and Trevor Crosse, who head up the life sciences stream. The firm also strengthened its disputes bench by hiring former Fieldfisher partner John Linneker, whose credentials include SkyKick v Sky before the Supreme Court.

This growth reflects Osborne Clarke’s strategy to balance technical depth with cross-border coordination across the UK and mainland Europe. While the UK team leads on SEP and life sciences matters, it collaborates closely with German, French, Belgian, and Polish offices, and leverages partnerships with firms such as Bardehle Pagenberg and Brinkhof for Unified Patent Court (UPC) and pan-European cases. Osborne Clarke’s London patent team is acknowledged as a rising force, especially for telecoms FRAND disputes and life-sciences litigation.

Key matters:

• Patent transactions & strategy

The team advised OMERS Life Sciences on acquisition of royalty entitlements from Enanta Pharmaceuticals during the Maviret deal.

• Avanci v Tesla

Represented Avanci in disputes with Tesla over 5G pool licensing, cementing the firm’s profile in telecommunications SEP litigation.

• PanOptis v Apple

Acting for PanOptis (co-counsel with EIP) in ongoing patent litigation concerning mobile-handset standards and FRAND issues.

• Amgen v Alexion & Amgen v Janssen (Biosimilars)

Led European life sciences litigation including revocation/infringement actions relating to Amgen’s anti-C5 and anti-IL12/23 antibodies—reflecting depth in biologics litigation.

Clients:

Amgen, Avanci, PanOptis, Apple, Tesla, Huawei, OMERS Life Sciences, Amgen, Santen, Unwired Planet